BackBridgeBio Oncology Therapeutics Overview

BridgeBio Oncology Therapeutics Receivables

Track BridgeBio Oncology Therapeutics's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

BridgeBio Oncology Therapeutics Receivables History

Loading

BridgeBio Oncology Therapeutics vs. peers: Receivables Comparison

Loading

BridgeBio Oncology Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

BridgeBio Oncology Therapeutics (BBOT) FAQ

The latest receivables for BBOT is $0 as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside BridgeBio Oncology Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BBOT's receivables moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BridgeBio Oncology Therapeutics's operating scale or balance-sheet position.

A receivables figure of $0 for BBOT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BBOT's receivables ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.